Antileishmanial drug development: Exploitation of parasite heme dependency

Molecular and Biochemical Parasitology

Volumn 126, Issue 1, 2003, Pages 43-49

  Kelly, Jane Xu ^a   Ignatushchenko, Marina V ^b   Bouwer, H G ^b,c   Peyton, David H ^a   Hinrichs, David J ^b,c   Winter, R W ^a,c   Riscoe, Michael ^a,b,c  

^a PORTLAND STATE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Drug design; Heme; Leishmania; Leishmania mexicana; Pentamidine; Persian Gulf War; Porphyrin; Xanthone

Indexed keywords

3,6 DI BETA N,N DIETHYLAMINOETHOXYXANTHONE; 3,6 DI DELTA N,N DIETHYLAMINOBUTOXYXANTHONE; 3,6 DI EPSILON N,N DIETHYLAMINOAMYLOXYXANTHONE; 3,6 DI GAMMA N,N DIETHYLAMINOPROPOXYXANTHONE; 3,6 DI ZETA N,N DIETHYLAMINOHEXYLOXYXANTHONE; ANTILEISHMANIAL AGENT; HEME; NITROGEN; PENTAMIDINE; UNCLASSIFIED DRUG; XANTHONE DERIVATIVE;

AMASTIGOTE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG POTENCY; DRUG PROTEIN BINDING; IC 50; IN VITRO STUDY; LEISHMANIA; LEISHMANIA MEXICANA; LEISHMANIASIS; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PHARMACOPHORE; PRIORITY JOURNAL;

ANIMALS; ANTIPROTOZOAL AGENTS; HEME; LEISHMANIA; LIFE CYCLE STAGES; MICE; MICE, INBRED BALB C; MODELS, BIOLOGICAL; XANTHENES; XANTHONES;

ANIMALIA; LEISHMANIA MEXICANA; MAMMALIA; PROTOZOA; TRYPANOSOMATIDAE;

EID: 12244297737     PISSN: 01666851     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-6851(02)00248-7     Document Type: Article

References (31)

1. Olliaro P., Bryceson A. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol. Today. 9:1993;323-328.
2. Magill A.J., Grogl M., Gasser R.A. Jr., Sun W., Oster C.N. Visceral infection caused by Leishmania tropica in veterans of operation desert storm [see comments]. New England J. Med. 328:1993;1383-1387.
3. Dedet J.P., Lambert M., Pratlong F. Leishmaniasis and human immunodeficiency virus infections. Presse Med. 24:1995;1036-1040.
4. Berman J.D. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. 24:1997;684-703.
5. Berenguer J., Gomez-Campdera F., Padilla B., Rodriguez-Ferrero M., Anaya F., Moreno S. Visceral leishmaniasis (kala-azar) in transplant recipients: case report and review. Transplantation. 65:1998;1401-1404.
6. Dedet J.P., Pratlong F. Leishmania, Trypanosoma and monoxenous trypanosomatids as emerging opportunistic agents. J. Eukaryot. Microbiol. 47:2000;37-39.
7. Ohl C., Hyams K., Malone J., Oldfield E. Leishmaniasis among desert storm veterans: a diagnostic and therapeutic dilemma. Military Med. 158:1993;726-729.
8. Magill A.J., Grogl M., Johnson S.C., Gasser R.A. Jr. Visceral infection due to Leishmania tropica in a veteran of operation desert storm who presented 2 years after leaving Saudi Arabia [letter]. Clin. Infect. Dis. 19:1994;805-806.
9. Sereno D., Lemesre J.L. Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob. Agents Chemother. 41:1997;972-976.
10. Campbell W.C. The chemotherapy of parasitic infections. J. Parasitol. 72:1986;45-61.
11. Lwoff M. The nutrition of parasitic flagellates (Trypanosomidae Trichomonadinae). In: Lwoff A, editor. Biochemistry and physiology of protozoa. New York: Academic Press; 1951. p. 131-82.
12. Salzman T.A., Stella A.M., Wider de Xifra E.A., Batlle A.M., Docampo R., Stoppani A.O. Porphyrin biosynthesis in parasitic hemoflagellates: functional and defective enzymes in Trypanosoma cruzi. Comp. Biochem. Physiol. B. 72:1982;663-667.
13. Salzman T., Battle A., Augluster J., De'Souza W. Heme synthesis in Crithidia deanei: influence of the endosymbiote. Int. J. Biochem. 17:1985;1343-1347.
14. Chang K.P., Chang C.S., Sassa S. Heme biosynthesis in bacterium-protozoon symbioses: enzymic defects in host hemoflagellates and complemental role of their intracellular symbiotes. Proc. Natl. Acad. Sci. U.S.A. 72:1975;2979-2983.
15. Steiger R.F., Steiger E. A defined medium for cultivating Leishmania donovani and L. braziliensis. J. Parasitol. 62:1976;1010-1011.
16. Chang C.S., Chang K.P. Heme requirement and acquisition by extracellular and intracellular stages of Leishmania mexicana amazonensis. Mol. Biochem. Parasitol. 16:1985;267-276.
17. Sah J.F., Ito H., Kolli B.K., Peterson D.A., Sassa S., Chang K.P. Genetic rescue of leishmania deficiency in porphyrin biosynthesis creates mutants suitable for analysis of cellular events in uroporphyria and for photodynamic therapy. J. Biol. Chem. 277:2002;14902-14909.
18. Galbraith R.A., McElrath M.J. Heme binding to Leishmania mexicana amazonensis. Mol. Biochem. Parasitol. 29:1988;47-53.
19. Winter R.W., Cornell K.A., Johnson L.L., Ignatushchenko M., Hinrichs D.J., Riscoe M.K. Potentiation of the antimalarial agent rufigallol. Antimicrob. Agents Chemother. 40:1996;1408-1411.
20. Winter R.W., Ignatushchenko M., Ogundahunsi O.A., Cornell K.A., Oduola A.M., Hinrichs D.J.et al. Potentiation of an antimalarial oxidant drug. Antimicrob. Agents Chemother. 41:1997;1449-1454.
21. Ignatushchenko M.V., Winter R.W., Bachinger H.P., Hinrichs D.J., Riscoe M.K. Xanthones as antimalarial agents: studies of a possible mode of action. FEBS Lett. 409:1997;67-73.
22. Xu Kelly J., Winter R., Peyton D.H., Hinrichs D.J., Riscoe M. Optimization of xanthones for antimalarial activity: the 3,6-bis-omega-diethylaminoalkoxyxanthone series. Antimicrob. Agents Chemother. 46:2002;144-150.
23. Xu Kelly J., Winter R., Cornea A., Peyton D.H., Hinrichs D.J., Riscoe M. The kinetics of uptake and accumulation of 3,6-bis-ω-diethylamino-amyloxyxanthone by the human malaria parasite Plasmodium falciparum. Mol. Biochem. Parasitol. 123:2002;47-54.
24. Callahan H.L., Portal A.C., Devereaux R., Grogl M. An axenic amastigote system for drug screening. Antimicrob. Agents Chemother. 41:1997;818-822.
25. Neal R.A., Croft S.L. An in-vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani. J. Antimicrob. Chemother. 14:1984;463-475.
26. Neal R.A., Croft S.L., Nelson D.J. Anti-leishmanial effect of allopurinol ribonucleoside and the related compounds, allopurinol, thiopurinol, thiopurinol ribonucleoside, and of formycin B, sinefungin and the lepidine WR6026. Trans. R. Soc. Trop. Med. Hyg. 79:1985;122-128.
27. Olliaro P.L., Goldberg D.E. The Plasmodium digestive vacuole: metabolic headquarters and choice drug target. Parasitol. Today. 11:1995;294-297.
28. Schneider I. Differentiation of larval Drosophilia eye-antennal discs in vitro. J. Exp. Zool. 156:1964;91-104.
29. Xu Kelly J., Winter R., Riscoe M., Peyton D.H. A spectroscopic investigation of the binding interactions between 4,5-dihydroxyxanthone and heme. J. Inorg. Biochem. 86:2001;617-625.
30. Lwoff M. Remarques sur la nutrition des Trypanosomides et des bactéries parahémotrophes le "fer actif" de baudisch. Ann. Inst. Pasteur. 51:1933;707-713.
31. MacIntyre A.C., Cutler D.J. Role of lysosomes in hepatic accumulation of chloroquine. J. Pharm Sci. 77:1988;196-199.